TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of VX-770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis (CF) Subjects With Genotype G551D
Brief Summary: The purpose of this study was to evaluate the safety and tolerability of ivacaftor in patients with cystic fibrosis (CF) who were aged 18 years or older and have a G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.


Options:
A: Arm Label: Dornase alfa; Type: EXPERIMENTAL; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Arm Label: isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Intervention Type: DRUG; Name: Dornase alfa (Pulmozyme); Assigned to Arm(s): Dornase alfa, isotonic saline | Intervention Type: DRUG; Name: isotonic saline; Assigned to Arm(s): Dornase alfa, isotonic saline
B: Arm Label: sodium chloride 6%; Type: EXPERIMENTAL; Interventions: Drug: sodium chloride 6% | Arm Label: sodium chloride 0,9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride 0,9% | Intervention Type: DRUG; Name: sodium chloride 6%; Assigned to Arm(s): sodium chloride 6% | Intervention Type: DRUG; Name: sodium chloride 0,9%; Assigned to Arm(s): sodium chloride 0,9%
C: Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-809, Drug: VX-770 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VX-770; Assigned to Arm(s): LUM/IVA
D: Arm Label: Ivacaftor Group A; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 25 mg/75 mg | Arm Label: Ivacaftor Group B; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 75 mg/150 mg | Arm Label: Ivacaftor Group C; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 150 mg or 250 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ivacaftor 25 mg/75 mg; Assigned to Arm(s): Ivacaftor Group A | Intervention Type: DRUG; Name: Ivacaftor 75 mg/150 mg; Assigned to Arm(s): Ivacaftor Group B | Intervention Type: DRUG; Name: Ivacaftor 150 mg or 250 mg; Assigned to Arm(s): Ivacaftor Group C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of VX-770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis (CF) Subjects With Genotype G551D
Brief Summary: The purpose of this study was to evaluate the safety and tolerability of ivacaftor in patients with cystic fibrosis (CF) who were aged 18 years or older and have a G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.


Options:
A: Arm Label: Ataluren; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Ivacaftor; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Ivacaftor
C: Arm Label: Ivacaftor Group A; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 25 mg/75 mg | Arm Label: Ivacaftor Group B; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 75 mg/150 mg | Arm Label: Ivacaftor Group C; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 150 mg or 250 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ivacaftor 25 mg/75 mg; Assigned to Arm(s): Ivacaftor Group A | Intervention Type: DRUG; Name: Ivacaftor 75 mg/150 mg; Assigned to Arm(s): Ivacaftor Group B | Intervention Type: DRUG; Name: Ivacaftor 150 mg or 250 mg; Assigned to Arm(s): Ivacaftor Group C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ivacaftor; Type: ACTIVE_COMPARATOR; Interventions: Drug: ivacaftor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ivacaftor; Assigned to Arm(s): Ivacaftor | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of VX-770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis (CF) Subjects With Genotype G551D
Brief Summary: The purpose of this study was to evaluate the safety and tolerability of ivacaftor in patients with cystic fibrosis (CF) who were aged 18 years or older and have a G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.


Options:
A: Arm Label: sodium chloride 6%; Type: EXPERIMENTAL; Interventions: Drug: sodium chloride 6% | Arm Label: sodium chloride 0,9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride 0,9% | Intervention Type: DRUG; Name: sodium chloride 6%; Assigned to Arm(s): sodium chloride 6% | Intervention Type: DRUG; Name: sodium chloride 0,9%; Assigned to Arm(s): sodium chloride 0,9%
B: Arm Label: Dornase alfa; Type: EXPERIMENTAL; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Arm Label: isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Intervention Type: DRUG; Name: Dornase alfa (Pulmozyme); Assigned to Arm(s): Dornase alfa, isotonic saline | Intervention Type: DRUG; Name: isotonic saline; Assigned to Arm(s): Dornase alfa, isotonic saline
C: Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-809, Drug: VX-770 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VX-770; Assigned to Arm(s): LUM/IVA
D: Arm Label: Ivacaftor Group A; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 25 mg/75 mg | Arm Label: Ivacaftor Group B; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 75 mg/150 mg | Arm Label: Ivacaftor Group C; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 150 mg or 250 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ivacaftor 25 mg/75 mg; Assigned to Arm(s): Ivacaftor Group A | Intervention Type: DRUG; Name: Ivacaftor 75 mg/150 mg; Assigned to Arm(s): Ivacaftor Group B | Intervention Type: DRUG; Name: Ivacaftor 150 mg or 250 mg; Assigned to Arm(s): Ivacaftor Group C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Isotonic Versus Hypotonic Saline for Maintenance Intravenous Fluid Therapy: A Pilot Randomized Trial
Brief Summary: Hyponatremia associated with administration of hypotonic intravenous (IV) fluids may have serious complications. It has recently been suggested that isotonic saline may be a more appropriate choice of maintenance IV fluid. This pilot and feasibility study aims to compare isotonic saline to 0.45% saline in hospitalized children requiring parenteral fluid support in order to:

Aim 1: To determine the feasibility of conducting a double-blind, randomized controlled trial comparing these solutions.

Aim 2a: To compare the rate of change in serum Na (mmol/L/hr) and the incidence of hyponatremia (Na \<136 mmol/L) between patients receiving isotonic and hypotonic intravenous fluids at at least 50% of the traditional maintenance rate for an interval of at least 8 hours.

Aim 2b: To compare the incidence of adverse events between the two IV fluid treatment groups.


Options:
A: Arm Label: Hypotonic; Type: ACTIVE_COMPARATOR; Interventions: Drug: hypotonic | Arm Label: Isotonic; Type: EXPERIMENTAL; Interventions: Drug: isotonic | Intervention Type: DRUG; Name: hypotonic; Assigned to Arm(s): Hypotonic | Intervention Type: DRUG; Name: isotonic; Assigned to Arm(s): Isotonic
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: 0.9% saline in 5% dextrose (intravenous) | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.45% saline in 5% dextrose (intravenous) | Intervention Type: DRUG; Name: 0.9% saline in 5% dextrose (intravenous); Assigned to Arm(s): A | Intervention Type: DRUG; Name: 0.45% saline in 5% dextrose (intravenous); Assigned to Arm(s): B
C: Arm Label: 0.9% NaCl; Type: EXPERIMENTAL; Interventions: Drug: 0.9% NaCl | Arm Label: 0.45% NaCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.45%NaCl | Intervention Type: DRUG; Name: 0.9% NaCl; Assigned to Arm(s): 0.9% NaCl | Intervention Type: DRUG; Name: 0.45%NaCl; Assigned to Arm(s): 0.45% NaCl
D: Arm Label: Isotonic fluid group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isotonic fluid | Arm Label: Fluid restriction group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hypotonic fluid | Arm Label: Hypotonic fluid group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hypotonic fluid | Intervention Type: DRUG; Name: Isotonic fluid; Assigned to Arm(s): Isotonic fluid group | Intervention Type: DRUG; Name: Hypotonic fluid; Assigned to Arm(s): Fluid restriction group | Intervention Type: DRUG; Name: Hypotonic fluid; Assigned to Arm(s): Hypotonic fluid group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Middle-School Based Primary Prevention Trial (HEALTHY)
Brief Summary: HEALTHY was a primary prevention trial conducted in 42 middle schools at 7 locations across the US to impact risk factors for type 2 diabetes in adolescents. Students were recruited at start of 6th grade (fall 2006) and followed to end of 8th grade (spring 2009). Half of the schools were randomized to receive an intervention that integrated four components: the school nutrition environment, physical education class activities, behavior change initiatives, and educational and promotional communications activities.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: The StepSmart Challenge | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The StepSmart Challenge; Assigned to Arm(s): Intervention
B: Arm Label: School based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: integrated program of nutrition, activity, behavior, and promotion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: integrated program of nutrition, activity, behavior, and promotion; Assigned to Arm(s): School based intervention
C: Arm Label: Texas I-CAN Active Math Lessons; Type: EXPERIMENTAL; Interventions: Behavioral: Texas I-CAN! | Arm Label: Texas I-CAN Active Language Arts Lessons; Type: EXPERIMENTAL; Interventions: Behavioral: Texas I-CAN! | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Texas I-CAN!; Assigned to Arm(s): Texas I-CAN Active Language Arts Lessons, Texas I-CAN Active Math Lessons
D: Arm Label: A+PAAC; Type: EXPERIMENTAL; Interventions: Behavioral: A+PAAC | Arm Label: CON; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CON | Intervention Type: BEHAVIORAL; Name: A+PAAC; Assigned to Arm(s): A+PAAC | Intervention Type: BEHAVIORAL; Name: CON; Assigned to Arm(s): CON

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Middle-School Based Primary Prevention Trial (HEALTHY)
Brief Summary: HEALTHY was a primary prevention trial conducted in 42 middle schools at 7 locations across the US to impact risk factors for type 2 diabetes in adolescents. Students were recruited at start of 6th grade (fall 2006) and followed to end of 8th grade (spring 2009). Half of the schools were randomized to receive an intervention that integrated four components: the school nutrition environment, physical education class activities, behavior change initiatives, and educational and promotional communications activities.


Options:
A: Arm Label: School-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Trial of Activity for Adolescent Girls (TAAG) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trial of Activity for Adolescent Girls (TAAG); Assigned to Arm(s): School-based intervention
B: Arm Label: School based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: integrated program of nutrition, activity, behavior, and promotion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: integrated program of nutrition, activity, behavior, and promotion; Assigned to Arm(s): School based intervention
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Short Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short-term educational program | Arm Label: Long Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Long-term educational program | Intervention Type: BEHAVIORAL; Name: Long-term educational program; Assigned to Arm(s): Long Intervention | Intervention Type: BEHAVIORAL; Name: Short-term educational program; Assigned to Arm(s): Short Intervention
D: Arm Label: multicomponent intervention; Type: EXPERIMENTAL; Interventions: Behavioral: a multicomponent intervention | Arm Label: usual-care control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: a multicomponent intervention; Assigned to Arm(s): multicomponent intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Middle-School Based Primary Prevention Trial (HEALTHY)
Brief Summary: HEALTHY was a primary prevention trial conducted in 42 middle schools at 7 locations across the US to impact risk factors for type 2 diabetes in adolescents. Students were recruited at start of 6th grade (fall 2006) and followed to end of 8th grade (spring 2009). Half of the schools were randomized to receive an intervention that integrated four components: the school nutrition environment, physical education class activities, behavior change initiatives, and educational and promotional communications activities.


Options:
A: Arm Label: School-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Trial of Activity for Adolescent Girls (TAAG) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trial of Activity for Adolescent Girls (TAAG); Assigned to Arm(s): School-based intervention
B: Arm Label: 7 Treatment Schools; Type: EXPERIMENTAL; Interventions: Behavioral: Positive Action program | Arm Label: 7 Control Schools; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Positive Action program; Assigned to Arm(s): 7 Treatment Schools
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Primary (Environmental) Weight Gain Prevention | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Primary (Environmental) Weight Gain Prevention, Behavioral: Secondary (Behavioral) Weight Gain Prevention | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Primary (Environmental) Weight Gain Prevention; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: BEHAVIORAL; Name: Secondary (Behavioral) Weight Gain Prevention; Assigned to Arm(s): Arm 2 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Arm 3
D: Arm Label: School based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: integrated program of nutrition, activity, behavior, and promotion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: integrated program of nutrition, activity, behavior, and promotion; Assigned to Arm(s): School based intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Middle-School Based Primary Prevention Trial (HEALTHY)
Brief Summary: HEALTHY was a primary prevention trial conducted in 42 middle schools at 7 locations across the US to impact risk factors for type 2 diabetes in adolescents. Students were recruited at start of 6th grade (fall 2006) and followed to end of 8th grade (spring 2009). Half of the schools were randomized to receive an intervention that integrated four components: the school nutrition environment, physical education class activities, behavior change initiatives, and educational and promotional communications activities.


Options:
A: Arm Label: Mobile phone based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone based intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mobile phone based intervention; Assigned to Arm(s): Mobile phone based intervention
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: environmental and behavioral change | Intervention Type: BEHAVIORAL; Name: environmental and behavioral change; Assigned to Arm(s): Intervention group
C: Arm Label: School based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: integrated program of nutrition, activity, behavior, and promotion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: integrated program of nutrition, activity, behavior, and promotion; Assigned to Arm(s): School based intervention
D: Arm Label: Menu Only intervention; Type: EXPERIMENTAL; Interventions: Other: Menu Only | Arm Label: Menu Plus Intervention; Type: EXPERIMENTAL; Interventions: Other: Menu Plus intervention | Intervention Type: OTHER; Name: Menu Only; Assigned to Arm(s): Menu Only intervention | Intervention Type: OTHER; Name: Menu Plus intervention; Assigned to Arm(s): Menu Plus Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Middle-School Based Primary Prevention Trial (HEALTHY)
Brief Summary: HEALTHY was a primary prevention trial conducted in 42 middle schools at 7 locations across the US to impact risk factors for type 2 diabetes in adolescents. Students were recruited at start of 6th grade (fall 2006) and followed to end of 8th grade (spring 2009). Half of the schools were randomized to receive an intervention that integrated four components: the school nutrition environment, physical education class activities, behavior change initiatives, and educational and promotional communications activities.


Options:
A: Arm Label: School based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: integrated program of nutrition, activity, behavior, and promotion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: integrated program of nutrition, activity, behavior, and promotion; Assigned to Arm(s): School based intervention
B: Intervention Type: BEHAVIORAL; Name: Nutritional and life style counseling; Assigned to Arm(s): N/A
C: Arm Label: A, Observational; Type: N/A; Interventions: N/A
D: Intervention Type: BEHAVIORAL; Name: Fat and carbohydrate controlled diet; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Middle-School Based Primary Prevention Trial (HEALTHY)
Brief Summary: HEALTHY was a primary prevention trial conducted in 42 middle schools at 7 locations across the US to impact risk factors for type 2 diabetes in adolescents. Students were recruited at start of 6th grade (fall 2006) and followed to end of 8th grade (spring 2009). Half of the schools were randomized to receive an intervention that integrated four components: the school nutrition environment, physical education class activities, behavior change initiatives, and educational and promotional communications activities.


Options:
A: Intervention Type: BEHAVIORAL; Name: FLOW; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: SelfHelp; Assigned to Arm(s): N/A
B: Arm Label: School based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: integrated program of nutrition, activity, behavior, and promotion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: integrated program of nutrition, activity, behavior, and promotion; Assigned to Arm(s): School based intervention
C: Intervention Type: BEHAVIORAL; Name: physical exercise; Assigned to Arm(s): N/A
D: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Intervention group

Answer: B